We present a case series of four patients with circumscribed choroidal hemangioma (CCH) treated with half-dose PDT, proposing this as a novel treatment protocol. Four patients with CCH were included, and then evaluated using multimodal imaging, including optical coherence tomography (OCT), fluorescein angiography, indocyanine green angiography, fundus autofluorescence, and ultrasound following treatment with half-dose and full-fluence PDT. Following half-dose PDT, all patients showed significant shrinkage of the hemangioma, functional improvement, and decrease of intra- and sub-retinal fluid. All patients remained stable after a single PDT treatment, with a follow-up of up to 60 months. No side effects were shown. This is the first report showing long term efficacy of half-dose PDT treatment in cases with CCH. The outcomes from this pilot study are comparable with results using full dose PDT protocols and it can be considered as a viable treatment option for CCH during the ongoing global verteporfin shortage.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9696376 | PMC |
http://dx.doi.org/10.3390/life12111748 | DOI Listing |
Am J Ophthalmol
November 2024
Department of Ophthalmology and Vision Sciences (M.M.P. and R.P.K.), University of Toronto, Toronto, Canada; John and Liz Tory Eye Centre (P.J.K., R.H.M., and R.P.K.), Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada. Electronic address:
Purpose: To investigate the comparative efficacy and safety of half-dose photodynamic therapy (PDT) and half-fluence PDT in the management of chronic central serous chorioretinopathy.
Design: Systematic review and meta-analysis.
Methods: A comprehensive literature search was conducted on Ovid MEDLINE, Embase, and the Cochrane Library, covering publications from January 2000 to March 2024.
Ophthalmology
October 2024
Department of Ophthalmology, Emory University School of Medicine, Atlanta, Georgia; Department of Ophthalmology, Truhlsen Eye Institute, University of Nebraska Medical Center, Omaha, Nebraska.
Purpose: To assess the safety and efficacy of the multiple therapeutic modalities for the treatment of central serous chorioretinopathy (CSCR).
Methods: A literature search of English-language studies in the PubMed database with no date restrictions was last conducted in May 2024. The combined searches yielded 612 citations, 31 of which were selected for full-text review and for inclusion in this assessment.
Ophthalmologica
October 2024
Department of Ophthalmology, Radboud University Medical Center, Nijmegen, The Netherlands.
Introduction: Half-dose photodynamic therapy (HD-PDT) with verteporfin is the mainstay treatment in central serous chorioretinopathy (CSC). Since 2021, there is a worldwide shortage of verteporfin. This called for adjustments of daily practice.
View Article and Find Full Text PDFActa Ophthalmol
October 2024
Eye Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
Graefes Arch Clin Exp Ophthalmol
October 2024
Department of Neurosciences, Imaging and Clinical Sciences, University "G. d'Annunzio" Chieti-Pescara, Via dei Vestini, 31, 66100, Chieti, CH, Italy.
Purpose: To compare the visual and anatomical results of navigated subthreshold micropulse laser (nSML) and photodynamic therapy (PDT) in the treatment of chronic central serous chorioretinopathy (CSCR).
Methods: Patients who underwent either half-dose PDT or nSML for the management of chronic CSCR were included in this study. Comprehensive ophthalmic examination, fundus autofluorescence, and spectral domain optical coherence tomography (SD-OCT) were performed at baseline and at 1-, 3-, and 6-month follow-up visits after nSML or PDT.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!